Analysts have recently evaluated Madrigal Pharmaceuticals and provided 12-month price targets. The average target is $497.5, accompanied by a high estimate of $554.00 and a low estimate of $428.00.

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Vanderpump Rules' star Scheana Shay is reacting to Peter Madrigal saying that he doesn't like the former members of the show.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

Madrigal's stock momentum is mixed, with a sharp decline over the last 3-6 months, but a strong performance over the 9-12 month period, showing a +133.40% increase.

Madrigal has also planned a “significant” point-of-care presence in specialists’ offices, she said, while an accompanying campaign website is decked out with information about both Rezdiffra ...